Quiver Bioscience received an undisclosed investment to advance its UBE3A antisense oligonucleotide program toward a development candidate for the treatment of chromosome 15q duplication syndrome, a rare neurodevelopmental disorder.
Quiver Bioscience received an undisclosed investment to advance its UBE3A antisense oligonucleotide program toward a development candidate for the treatment of chromosome 15q duplication syndrome, a rare neurodevelopmental disorder.